Literature DB >> 30597624

Longitudinal tau accumulation and atrophy in aging and alzheimer disease.

Theresa M Harrison1, Renaud La Joie2, Anne Maass1,3, Suzanne L Baker4, Kaitlin Swinnerton1, Laura Fenton1, Taylor J Mellinger2, Lauren Edwards2, Julie Pham2, Bruce L Miller2, Gil D Rabinovici2, William J Jagust1,4.   

Abstract

OBJECTIVE: To determine the rate of tau accumulation in healthy older adults (OA) and patients with Alzheimer disease (AD), as well as the relationship of tau accumulation to cortical atrophy.
METHODS: Two longitudinal flortaucipir (FTP) positron emission tomography (PET) and magnetic resonance imaging (MRI) scans were acquired from 42 OA (21 Pittsburg compound B [PiB]+ , age = 77.6 ± 4.6 years, 25 female [F]/17 male [M]) and 19 PiB+ patients with AD (age = 63.1 ± 10.3 years, 12 F/7 M) over 1 to 3 years of follow-up. FTP change, structural MRI measures of atrophy, and cross-modal correlations were examined on a voxelwise level. Regional annual percentage change in FTP was also calculated.
RESULTS: Voxelwise FTP change in AD showed the greatest increases in lateral and medial frontal lobes. Atrophy over the same interval was more widespread and included posteromedial cortical areas, where tau accumulation rates were lower. In OA, FTP binding increased in bilateral temporal lobe and retrosplenial cortex, accompanied by atrophy in the same regions. There were no associations between voxelwise change in FTP and sex, PiB, or APOE. Regional FTP significantly increased at follow-up in OA and patients with AD. Mixed effects models showed greater FTP increases in AD compared to OA, and no differences within OA based on PiB status.
INTERPRETATION: Our findings indicate that tau accumulates even in amyloid-negative healthy OA and this process can be measured with in vivo tau-PET. In OA, tau accumulation and atrophy share a similar topography. In AD, tau increases more rapidly and accumulation occurs in frontal regions that are not yet undergoing significant atrophy. Ann Neurol 2019; 1-12 ANN NEUROL 2019;85:229-240.
© 2018 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30597624      PMCID: PMC6579738          DOI: 10.1002/ana.25406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

2.  Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease.

Authors:  Armin von Gunten; Enikö Kövari; Thierry Bussière; Claire-Bénédicte Rivara; Gabriel Gold; Constantin Bouras; Patrick R Hof; Panteleimon Giannakopoulos
Journal:  Neurobiol Aging       Date:  2005-04-26       Impact factor: 4.673

Review 3.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

4.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

5.  Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings.

Authors:  Samuel N Lockhart; Nagehan Ayakta; Joseph R Winer; Renaud La Joie; Gil D Rabinovici; William J Jagust
Journal:  Neurology       Date:  2017-02-10       Impact factor: 9.910

6.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Authors:  Adam J Schwarz; Peng Yu; Bradley B Miller; Sergey Shcherbinin; James Dickson; Michael Navitsky; Abhinay D Joshi; Michael D Devous; Mark S Mintun
Journal:  Brain       Date:  2016-03-02       Impact factor: 13.501

7.  PET Imaging of Tau Deposition in the Aging Human Brain.

Authors:  Michael Schöll; Samuel N Lockhart; Daniel R Schonhaut; James P O'Neil; Mustafa Janabi; Rik Ossenkoppele; Suzanne L Baker; Jacob W Vogel; Jamie Faria; Henry D Schwimmer; Gil D Rabinovici; William J Jagust
Journal:  Neuron       Date:  2016-03-02       Impact factor: 17.173

8.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

Review 9.  Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.

Authors:  Michel Goedert; Masami Masuda-Suzukake; Benjamin Falcon
Journal:  Brain       Date:  2016-09-21       Impact factor: 13.501

10.  Symmetric diffeomorphic modeling of longitudinal structural MRI.

Authors:  John Ashburner; Gerard R Ridgway
Journal:  Front Neurosci       Date:  2013-02-05       Impact factor: 4.677

View more
  88 in total

1.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.

Authors:  Irene Sintini; Jonathan Graff-Radford; Matthew L Senjem; Christopher G Schwarz; Mary M Machulda; Peter R Martin; David T Jones; Bradley F Boeve; David S Knopman; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

Review 2.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

3.  Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.

Authors:  Alexis Moscoso; Michel J Grothe; Michael Schöll
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-21       Impact factor: 9.236

4.  Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid.

Authors:  Daniel Albrecht; A Lisette Isenberg; Joy Stradford; Teresa Monreal; Abhay Sagare; Maricarmen Pachicano; Melanie Sweeney; Arthur Toga; Berislav Zlokovic; Helena Chui; Elizabeth Joe; Lon Schneider; Peter Conti; Kay Jann; Judy Pa
Journal:  J Neurosci       Date:  2020-10-12       Impact factor: 6.167

Review 5.  Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.

Authors:  Hiroshi Matsuda; Yoko Shigemoto; Noriko Sato
Journal:  Jpn J Radiol       Date:  2019-09-06       Impact factor: 2.374

6.  Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.

Authors:  Matthew R Scott; Olivia L Hampton; Rachel F Buckley; Jasmeer P Chhatwal; Bernard J Hanseeuw; Heidi Il Jacobs; Michael J Properzi; Justin S Sanchez; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2020-06-05       Impact factor: 6.556

7.  Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-11-19       Impact factor: 4.027

8.  Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Authors:  Renaud La Joie; Adrienne V Visani; Suzanne L Baker; Jesse A Brown; Viktoriya Bourakova; Jungho Cha; Kiran Chaudhary; Lauren Edwards; Leonardo Iaccarino; Mustafa Janabi; Orit H Lesman-Segev; Zachary A Miller; David C Perry; James P O'Neil; Julie Pham; Julio C Rojas; Howard J Rosen; William W Seeley; Richard M Tsai; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Sci Transl Med       Date:  2020-01-01       Impact factor: 17.956

9.  Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease.

Authors:  Diana Younan; Andrew J Petkus; Keith F Widaman; Xinhui Wang; Ramon Casanova; Mark A Espeland; Margaret Gatz; Victor W Henderson; JoAnn E Manson; Stephen R Rapp; Bonnie C Sachs; Marc L Serre; Sarah A Gaussoin; Ryan Barnard; Santiago Saldana; William Vizuete; Daniel P Beavers; Joel A Salinas; Helena C Chui; Susan M Resnick; Sally A Shumaker; Jiu-Chiuan Chen
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 10.  Amyloid-β-independent regulators of tau pathology in Alzheimer disease.

Authors:  Rik van der Kant; Lawrence S B Goldstein; Rik Ossenkoppele
Journal:  Nat Rev Neurosci       Date:  2019-11-28       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.